SE9803929D0 - Antiviral formulation - Google Patents

Antiviral formulation

Info

Publication number
SE9803929D0
SE9803929D0 SE9803929A SE9803929A SE9803929D0 SE 9803929 D0 SE9803929 D0 SE 9803929D0 SE 9803929 A SE9803929 A SE 9803929A SE 9803929 A SE9803929 A SE 9803929A SE 9803929 D0 SE9803929 D0 SE 9803929D0
Authority
SE
Sweden
Prior art keywords
antiviral
weight
antiviral formulation
prophylaxis
compositions
Prior art date
Application number
SE9803929A
Other languages
English (en)
Swedish (sv)
Inventor
Gunilla Lekare
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9803929(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir Ab filed Critical Medivir Ab
Priority to SE9803929A priority Critical patent/SE9803929D0/xx
Publication of SE9803929D0 publication Critical patent/SE9803929D0/xx
Priority to ES99972109T priority patent/ES2233104T3/es
Priority to IL14270299A priority patent/IL142702A0/xx
Priority to NZ511832A priority patent/NZ511832A/en
Priority to HK02104279.2A priority patent/HK1042440B/zh
Priority to KR1020017006232A priority patent/KR100608963B1/ko
Priority to AT99972109T priority patent/ATE288283T1/de
Priority to PCT/SE1999/002043 priority patent/WO2000029027A1/en
Priority to DE69923584T priority patent/DE69923584T2/de
Priority to SI9930733T priority patent/SI1131104T1/xx
Priority to JP2000582073A priority patent/JP2002529520A/ja
Priority to PT99972109T priority patent/PT1131104E/pt
Priority to AU14364/00A priority patent/AU772435B2/en
Priority to CNB998133825A priority patent/CN1160128C/zh
Priority to DK99972109T priority patent/DK1131104T3/da
Priority to EP99972109A priority patent/EP1131104B1/en
Priority to CA002351463A priority patent/CA2351463C/en
Priority to TW088119865A priority patent/TW589191B/zh
Priority to MYPI99004979A priority patent/MY122397A/en
Priority to EG146899A priority patent/EG23853A/xx
Priority to ARP990105846A priority patent/AR023705A1/es
Priority to IL142702A priority patent/IL142702A/en
Priority to ZA200103335A priority patent/ZA200103335B/en
Priority to US10/334,487 priority patent/US7223387B2/en
Priority to JP2011087438A priority patent/JP5420583B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9803929A 1998-11-18 1998-11-18 Antiviral formulation SE9803929D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE9803929A SE9803929D0 (sv) 1998-11-18 1998-11-18 Antiviral formulation
EP99972109A EP1131104B1 (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
CA002351463A CA2351463C (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
PT99972109T PT1131104E (pt) 1998-11-18 1999-11-12 Formulacoes antivirais compreendendo propilenoglicol e um ester de acido isopropilalcanoico
AU14364/00A AU772435B2 (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
NZ511832A NZ511832A (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
HK02104279.2A HK1042440B (zh) 1998-11-18 1999-11-12 含有丙二醇和異丙基鏈烷酸酯的抗病毒製劑
KR1020017006232A KR100608963B1 (ko) 1998-11-18 1999-11-12 프로필렌 글리콜 및 이소프로필 알칸산 에스테르를포함하는 항바이러스 제제
AT99972109T ATE288283T1 (de) 1998-11-18 1999-11-12 Antivirale zusammensetzungen welche propylenglykol und isopropyl-alkansäureester enthalten
PCT/SE1999/002043 WO2000029027A1 (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
DE69923584T DE69923584T2 (de) 1998-11-18 1999-11-12 Antivirale zusammensetzungen welche propylenglykol und isopropyl-alkansäureester enthalten
SI9930733T SI1131104T1 (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
JP2000582073A JP2002529520A (ja) 1998-11-18 1999-11-12 プロピレングリコールおよびアルカン酸イソプロピルエステルを含む抗ウイルス製剤
ES99972109T ES2233104T3 (es) 1998-11-18 1999-11-12 Formulaciones antivirales que comprenden propilenglicol y un ester isopropilico de acido alcanoico.
IL14270299A IL142702A0 (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
CNB998133825A CN1160128C (zh) 1998-11-18 1999-11-12 含有丙二醇和异丙基链烷酸酯的抗病毒制剂
DK99972109T DK1131104T3 (da) 1998-11-18 1999-11-12 Antivirale formuleringer, der omfatter propylenglycol og en isopropyl-alkansyreester
TW088119865A TW589191B (en) 1998-11-18 1999-11-15 Topical compositions comprising antiinflammatory glucocorticoid and nucleoside analogue antiviral agent in pharmaceutical carrier
EG146899A EG23853A (en) 1998-11-18 1999-11-16 Antiviral glucocorticoid formulation comprising propylene glycol and ispropyl alkanoic acid esters
MYPI99004979A MY122397A (en) 1998-11-18 1999-11-16 Acyclic antiviral and hydrocortisone combination comprising propylene glycol and alkanoic acid ester
ARP990105846A AR023705A1 (es) 1998-11-18 1999-11-17 COMPOSICIoN ToPICA QUE COMPRENDE EL GLUCOCORTICOIDE ANTIINFLAMATORIO HIDROCORTISONA Y UN AGENTE ANTIVIRAL ANALOGO DE NUCLEOSIDO ACICLOVIR Y EL USO DE LA MISMA
IL142702A IL142702A (en) 1998-11-18 2001-04-19 Antiviral formulations consisting of propylene glycol ester of alkanoic isopropyl acid
ZA200103335A ZA200103335B (en) 1998-11-18 2001-04-24 Antiviral formulations comprising propylene glycol and an isopropyl alkonoic acid ester.
US10/334,487 US7223387B2 (en) 1998-11-18 2002-12-30 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
JP2011087438A JP5420583B2 (ja) 1998-11-18 2011-04-11 プロピレングリコールおよびアルカン酸イソプロピルエステルを含む抗ウイルス製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9803929A SE9803929D0 (sv) 1998-11-18 1998-11-18 Antiviral formulation

Publications (1)

Publication Number Publication Date
SE9803929D0 true SE9803929D0 (sv) 1998-11-18

Family

ID=20413320

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803929A SE9803929D0 (sv) 1998-11-18 1998-11-18 Antiviral formulation

Country Status (21)

Country Link
EP (1) EP1131104B1 (enExample)
JP (2) JP2002529520A (enExample)
KR (1) KR100608963B1 (enExample)
CN (1) CN1160128C (enExample)
AR (1) AR023705A1 (enExample)
AT (1) ATE288283T1 (enExample)
AU (1) AU772435B2 (enExample)
CA (1) CA2351463C (enExample)
DE (1) DE69923584T2 (enExample)
DK (1) DK1131104T3 (enExample)
EG (1) EG23853A (enExample)
ES (1) ES2233104T3 (enExample)
HK (1) HK1042440B (enExample)
IL (2) IL142702A0 (enExample)
MY (1) MY122397A (enExample)
NZ (1) NZ511832A (enExample)
PT (1) PT1131104E (enExample)
SE (1) SE9803929D0 (enExample)
TW (1) TW589191B (enExample)
WO (1) WO2000029027A1 (enExample)
ZA (1) ZA200103335B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100956369B1 (ko) * 2001-11-19 2010-05-10 메디진 아게 바이러스성 피부 질환 및 종양 질환 치료용 약제
ZA200602544B (en) 2003-10-09 2007-06-27 Medigene Ag The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
JP4972062B2 (ja) * 2008-03-17 2012-07-11 メディヴィル・アクチエボラーグ 抗ウイルス製剤
ES2955089T3 (es) * 2018-08-17 2023-11-28 Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi Composición tópica estable en fase que comprende aciclovir e hidrocortisona

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438585B (en) * 1995-02-06 2001-06-07 Astra Ab Pharmaceutical compositions for topical administration for prophylaxis and/or treatment of herpesvirus infections
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers

Also Published As

Publication number Publication date
HK1042440A1 (en) 2002-08-16
EG23853A (en) 2007-11-06
AU1436400A (en) 2000-06-05
AU772435B2 (en) 2004-04-29
TW589191B (en) 2004-06-01
CN1326364A (zh) 2001-12-12
DK1131104T3 (da) 2005-03-14
ES2233104T3 (es) 2005-06-01
IL142702A (en) 2006-07-05
HK1042440B (zh) 2005-04-29
EP1131104B1 (en) 2005-02-02
ZA200103335B (en) 2002-07-24
MY122397A (en) 2006-04-29
NZ511832A (en) 2003-09-26
ATE288283T1 (de) 2005-02-15
CN1160128C (zh) 2004-08-04
CA2351463C (en) 2009-10-13
DE69923584T2 (de) 2006-03-23
JP2002529520A (ja) 2002-09-10
IL142702A0 (en) 2002-03-10
KR20010075720A (ko) 2001-08-09
PT1131104E (pt) 2005-03-31
EP1131104A1 (en) 2001-09-12
WO2000029027A1 (en) 2000-05-25
JP5420583B2 (ja) 2014-02-19
CA2351463A1 (en) 2000-05-25
AR023705A1 (es) 2002-09-04
JP2011157392A (ja) 2011-08-18
KR100608963B1 (ko) 2006-08-09
DE69923584D1 (de) 2005-03-10

Similar Documents

Publication Publication Date Title
CA2211389A1 (en) Novel pharmaceutical combination
MY107341A (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use
CA2141953A1 (en) Pharmaceutical formulations of interleukin-1 inhibitors
GB9905425D0 (en) Pharmaceutical composition
PT716600E (pt) Composicoes para administracao topica contendo derivados do acido 3-benzoilfenilacetico para o tratamento de doencas inflamatorias oftalmicas
AU1937395A (en) Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
CA2190505A1 (en) Use of gel formulations as dressing agents
CA2136331A1 (en) New pharmaceutical uses of krill enzymes
IL128969A (en) Antimicrobial cosmetic compositions
IT1263013B (it) Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
CA2031817A1 (en) Use of thrombospondin to promote wound healing
ES2065647T3 (es) Empleo cosmetico de una composicion que tiene una actividad antieritematosa.
FI955403A0 (fi) Valeltavia koostumuksia, jotka sisältävät polymeerimateriaalia, glykoleja ja glyseridejä
ES2124395T3 (es) Utilizacion de esteres de diglicerina contra las impurezas de la piel.
SE9401005L (sv) Farmaceutisk komposition med analgetisk aktivitet
AU3435189A (en) Topically applied gold organic complex
AU1876792A (en) Pharmacologically enhanced formulations
ATE525063T1 (de) Antivirale formulierung
SE9803929D0 (sv) Antiviral formulation
CA2417935A1 (en) Anti-inflammatory medicament
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
IL107755A0 (en) Pharmacuetical compositions for the treatment and prophylaxis of parasitic infections
ITRM990339A0 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali deriva
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
ATE102934T1 (de) Fluorierte flavon-essigsaeure.